|
Inovio Announces Analysis Of VGX-3100 Phase 2b Data.
Inovio Pharmaceuticals, Inc announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success.
|
|
Agendia collaborates with prestigious cancer center,institut curie, for mammaprint kit co-validation study
Agendia co-validation partnership for Agendia new in vitro diagnostic MammaPrint BluePrint Breast Cancer Risk of Recurrence and Molecular Subtyping Kit...
|
|